Fortress Biotech, Inc. (FBIO) is a Nasdaq-listed biopharmaceutical company that acquires, develops, and monetizes drug assets, often through partner companies and subsidiaries. Its analyst coverage is thin, so the central target reflects only two individually attributable price targets rather than a broad consensus.
H.C. Wainwright analyst Joseph Pantginis maintains a Buy rating with a $17 target, reiterated in early 2026 after a prior reduction from $26. Alliance Global Partners analyst Scott Henry holds a Buy rating with a $5 target, raised from $4.50 in May 2026 and reaffirmed in August 2026, citing the value of the company's cash balance and its stake in Journey Medical (DERM).
The arithmetic mean of these two targets is $11.00, which I round to $11. The $5-to-$17 spread is extraordinarily wide, underscoring that the two firms hold fundamentally different views of what the company's portfolio is worth. Some aggregators display only the single $17 figure, while others report an $11 average; neither is an official consensus.
The stock closed at $1.93 on October 27, 2026, near the lower end of its 52-week range of $1.83 to $4.53. Moving from roughly $1.93 to $11 represents an advance of about 470%, which is a very large required move by any standard.
The path would likely depend less on incremental earnings and more on a re-rating of the company's asset base. Fortress reported roughly $196.6 million in total cash against a market capitalization of only about $62 million, giving the company a negative enterprise value. Its model of licensing and then selling or partnering drug candidates has produced notable transactions, including the sale of the UNLOXCYT (cosibelimab) checkpoint-antibody asset and the monetization of a priority review voucher.
The stock sits below its 50-day simple moving average near $2.36 and its 200-day moving average near $2.82, indicating a weak near-term trend. The 52-week low around $1.83, reached in October 2026, is the key downside support level. On the upside, resistance is evident near $2.36, then $2.82, with the 52-week high at $4.53 representing the next major structural level before any move toward double digits could be contemplated.
Analyst price targets are typically framed around a roughly 12-month research horizon, though the two firms covering FBIO do not publish identical timelines. Investors should watch quarterly results, cash runway and any financing activity, updates on the Journey Medical stake and Emrosi (rosacea) launch, clinical and regulatory milestones across the portfolio, and any new monetization transactions. Changes to either analyst target would also be meaningful given how few cover the name.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than through manual screening. For those tracking volatile small-cap biotech names like FBIO, automated signal tools can help filter noise and surface actionable changes in momentum.
Whether Fortress Biotech can reach $11 depends on the market deciding to recognize value that it currently appears to ignore. The central target is the average of just two widely divergent analyst views, so it should be treated as a rough reference rather than a precise forecast. The required move of roughly 470% is very large, and the bull case rests on asset monetization and a cash-rich balance sheet, while the bear case centers on recurring losses, dilution, and a stubborn holding-company discount. Neither the support nor the obstacle is trivial, and the path forward will likely be dictated by concrete corporate events rather than broad sector sentiment. Investors should monitor those catalysts closely and draw their own conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, FBIO has been loosely correlated with AXON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if FBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To FBIO | 1D Price Change % | ||
|---|---|---|---|---|
| FBIO | 100% | +5.24% | ||
| AXON - FBIO | 38% Loosely correlated | +4.26% | ||
| QSI - FBIO | 32% Poorly correlated | -0.78% | ||
| CLYM - FBIO | 32% Poorly correlated | +4.34% | ||
| HYFT - FBIO | 32% Poorly correlated | N/A | ||
| EDIT - FBIO | 31% Poorly correlated | -4.99% | ||
More | ||||